<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13433">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02111707</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041158</org_study_id>
    <nct_id>NCT02111707</nct_id>
  </id_info>
  <brief_title>Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)</brief_title>
  <official_title>Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the timing of administration of indomethacin affects the primary outcome of
      post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive
      pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of Post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the severity of post-ERCP pancreatitis between the 2 groups studied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Rectal Indomethacin pre-ERCP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Indomethacin post-ERCP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rectal indomethacin 100mg one time before or after ERCP</intervention_name>
    <description>Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.</description>
    <arm_group_label>Rectal Indomethacin pre-ERCP</arm_group_label>
    <arm_group_label>Rectal Indomethacin post-ERCP</arm_group_label>
    <other_name>Indocid 100mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients referred for ERCP at the University of Alberta

          -  Age greater than 18 years

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Acute pancreatitis

          -  Active peptic ulcer disease

          -  Rectal disease

          -  Aspirin-induced asthma

          -  Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity

          -  Pregnancy

          -  Breast feeding

          -  Creatinine clearance &lt; 30 ml/min
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergio Zepeda-Gomez</last_name>
    <email>zepedago@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Zepeda-Gomez, Assistant Professor</last_name>
      <phone>780-248-1578</phone>
      <email>zepedago@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Pernilla D'Souza, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gurpal Sandha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Sultanian, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aldo Montano-Loza, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Zepeda-Gomez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007 May;102(5):978-83. Epub 2007 Mar 13.</citation>
    <PMID>17355281</PMID>
  </results_reference>
  <results_reference>
    <citation>Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22.</citation>
    <PMID>22494121</PMID>
  </results_reference>
  <results_reference>
    <citation>Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91.</citation>
    <PMID>12806612</PMID>
  </results_reference>
  <results_reference>
    <citation>Montaño Loza A, Rodríguez Lomelí X, García Correa JE, Dávalos Cobián C, Cervantes Guevara G, Medrano Muñoz F, Fuentes Orozco C, González Ojeda A. [Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes]. Rev Esp Enferm Dig. 2007 Jun;99(6):330-6. Spanish.</citation>
    <PMID>17883296</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
